

THE CLINICAL PICTURE

SERGIO VAÑO-GALVÁN, MD
Department of Dermatology, Ramón y Cajal
Hospital, University of Alcalá, Madrid, Spain

SONSOLES ABOÍN, MD
Department of Dermatology, Ramón y Cajal
Hospital, Madrid, Spain

SONIO BEÀ-ARDEBOL, MD
Department of Dermatology, Ramón y Cajal
Hospital, Madrid, Spain

**JUAN LUIS SANTIAGO
SÁNCHEZ-MATEOS, MD**
Department of Dermatology, Ramón y Cajal
University Hospital, Madrid, Spain

The Clinical Picture

Sudden hair loss associated with trachyonychia

A 30-YEAR-OLD WOMAN has a 6-month history of episodes of sudden loss of hair in well-demarcated, localized areas of her scalp. She is otherwise well and has had no pruritus or pain. She has had atopic dermatitis since childhood, occasionally treated with topical corticosteroids, and localized facial vitiligo for the past 8 years. She takes no systemic drugs. She has no family history of similar lesions.

Her head has multiple round to oval skin-colored, well-demarcated alopecic patches on the vertex (**FIGURE 1**). Her fingernails and toenails have a “sandpapered” appearance, with a rough, lusterless nail plate characteristic of trachyonychia (**FIGURE 2**). Otherwise, the physical examination is normal.

Histologic examination of the scalp shows a peribulbar lymphocytic infiltrate similar in appearance to a swarm of bees. Routine laboratory tests, including thyroid hormones and thyroid-stimulating hormone, are normal.

Q: What is the most likely diagnosis?

- Telogen effluvium
- Syphilitic alopecia
- Alopecia areata
- Trichotillomania
- Androgenetic alopecia

A: The correct answer is alopecia areata, a disease characterized by recurrent episodes of sudden hair loss and nail changes such as trachyonychia. It can affect any hair-bearing area, but the scalp is the most common site (90% of cases).¹ The condition can range from a single patch of hair loss to complete loss of hair on the scalp (alopecia totalis) or the entire body (alopecia universalis).

The characteristic lesion is a round or



FIGURE 1. Skin-colored alopecic patches on the vertex



FIGURE 2. Trachyonychia

oval, totally bald, smooth patch, which may have a mild peachy hue. A frequent feature is “exclamation-mark” hairs at the margin of the patch, appearing as broad distal hair shafts, narrow proximally. Active alopecia areata can be confirmed with a positive hair-pull test.

Nail involvement is common in alopecia areata, particularly in severe forms. Pitting is the most common finding, but other abnormalities such as trachyonychia have been reported.¹ Nail plate pitting tends to be more shallow and regularly spaced than in psoriatic nail pitting. Trachyonychia, also known as “twenty-nail dystrophy,” is the term used to describe nail plate roughness, pitting, and ridging, affecting 1 to 20 nails. It is associated with a number of skin conditions, including alopecia areata, psoriasis, lichen planus, atopic dermatitis, and ichthyosis vulgaris.⁴

■ AN AUTOIMMUNE DISEASE

The precise cause of this common disorder has not been elucidated, but substantial evidence suggests that it is an organ-specific autoimmune disease that targets hair follicles.¹⁻³

The current hypothesis is that the hair follicle is a site of immune privilege. In alopecia areata, increased expression of major histocompatibility complex class I molecules and down-regulation of immunosuppressants allows the immune system to recognize the immune-privileged follicle antigens.² Several autoimmune diseases, such as thyroid disorders, vitiligo, pernicious anemia, diabetes mellitus, lupus erythematosus, myasthenia gravis, lichen planus, autoimmune polyendocrine syndrome type I, and celiac disease, have been reported in association with alopecia areata¹; thyroid disorders and vitiligo have the strongest relationship. Other diseases reported to be associated with alopecia areata at a higher rate than in the general population are atopic dermatitis and Down syndrome.¹

■ NO CURE, BUT TREATABLE

The choice of treatment depends on the patient’s age and the extent of alopecia activity.⁵ No cure or preventive treatment has been found, so treatments are directed toward halting disease activity.

Corticosteroids are currently the most pop-

ular form of treatment, and published reports support their efficacy.¹ Topical and intralesional steroids are usually the first-line treatment for localized disease. Systemic steroids are rarely used, except in cases with rapid progression.

Other treatments that have been used with some success include minoxidil (Rogaine), anthralin (Dritho-Scalp), contact sensitizers (dinitrochlorobenzene, diphenylcyclopropenone), PUVA (psoralen plus ultraviolet A light), and cyclosporine (Sandimmune).¹ If the alopecia is resistant to therapy, hair prostheses can be recommended.

Indicators of poor prognosis (ie, hair that will not regrow completely) include atopy, the presence of other immune diseases, young age at onset, family history, nail dystrophy, extensive hair loss, and ophiasis (a continuous band of baldness involving the temporal and occipital margins).

Because current treatments may not bring results for 3 to 6 months, it is essential to reassure and inform the patient about the results that can be expected. Physicians should also inform patients of the chronic relapsing nature of alopecia areata and its unpredictable course. Although the condition does not threaten the patient’s general health and does not cause scarring, its psychological impact is significant. Support groups such as the National Alopecia Areata Foundation (www.naaf.org) can help. ■

■ REFERENCES

1. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. *Int J Dermatol* 2007; 46:121-131.
2. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. *J Invest Dermatol Symp Proc* 2003; 8:188-194.
3. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia areata: autoimmune basis of hair loss. *Eur J Dermatol* 2004; 14:364-370.
4. Blanco FP, Scher RK. Trachyonychia: case report and review of the literature. *J Drugs Dermatol* 2006; 5:469-472.
5. Dombrowski NC, Bergfeld WF. Alopecia areata: what to expect from current treatments. *Cleve Clin J Med* 2005; 72:758-768.

ADDRESS: Sergio Vañó-Galván, MD, Department of Dermatology, Ramón y Cajal University Hospital, Carretera de Colmenar Viejo, km 9.100, 28034 Madrid, Spain; e-mail sergiovano@yahoo.es.

Evidence suggests that alopecia is an autoimmune disease that targets hair follicles